Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 2NET 1Endocrine 1

Conditions

Neuroendocrine Tumors 3Neuroblastoma 1Meningioma 1Medulloblastoma 1Gastro-enteropancreatic neuroendocrine tumor 1Carcinoid Tumor 1

Interventions

Proton Therapy 290Y-octreotide, DOTA-Tyr(3)- 2olaparib 1lutetium Lu 177 dotatate 1gallium Ga 68 dotatate 1entinostat 1arginyllysine 1Whole Body Imaging 1Surveys and Questionnaires 1Radiosurgery 1Radiation Dose Hypofractionation 1Protons 1Photochemotherapy 1Neuropsychological Tests 1Magnetic Resonance Spectroscopy 1Fentanyl 1Dihematoporphyrin Ether 1Aminolevulinic Acid 1Amino Acids 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Meningioma × arginyllysine × Endocrine × Clear all
NCT03273712 2023-02-09

Dosimetry-Guided, Peptide Receptor Radiotherapy (PRRT) With 90Y-DOTA- tyr3-Octreotide (90Y-DOTATOC)

University of Iowa

Phase 2 Completed
39 enrolled 9 charts
CNSEndocrineNET

Medulloblastoma, Meningioma, Neuroblastoma, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡